MX2024009251A - Proteinas biespecificas activables anti-cd47 y anti-pd-l1 y usos de las mismas. - Google Patents

Proteinas biespecificas activables anti-cd47 y anti-pd-l1 y usos de las mismas.

Info

Publication number
MX2024009251A
MX2024009251A MX2024009251A MX2024009251A MX2024009251A MX 2024009251 A MX2024009251 A MX 2024009251A MX 2024009251 A MX2024009251 A MX 2024009251A MX 2024009251 A MX2024009251 A MX 2024009251A MX 2024009251 A MX2024009251 A MX 2024009251A
Authority
MX
Mexico
Prior art keywords
proteins
activatable
activatable bispecific
protein molecules
bispecific anti
Prior art date
Application number
MX2024009251A
Other languages
English (en)
Spanish (es)
Inventor
William James Jonathan Finlay
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of MX2024009251A publication Critical patent/MX2024009251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024009251A 2022-01-31 2023-01-31 Proteinas biespecificas activables anti-cd47 y anti-pd-l1 y usos de las mismas. MX2024009251A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305003P 2022-01-31 2022-01-31
US202263309759P 2022-02-14 2022-02-14
US202263342283P 2022-05-16 2022-05-16
US202263348842P 2022-06-03 2022-06-03
PCT/EP2023/052366 WO2023144423A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2024009251A true MX2024009251A (es) 2024-08-06

Family

ID=85199086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009251A MX2024009251A (es) 2022-01-31 2023-01-31 Proteinas biespecificas activables anti-cd47 y anti-pd-l1 y usos de las mismas.

Country Status (9)

Country Link
US (1) US20250002585A1 (https=)
EP (1) EP4473012A1 (https=)
JP (1) JP2025504955A (https=)
KR (1) KR20240137084A (https=)
AU (1) AU2023210844A1 (https=)
CA (1) CA3251615A1 (https=)
IL (1) IL314395A (https=)
MX (1) MX2024009251A (https=)
WO (1) WO2023144423A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Also Published As

Publication number Publication date
IL314395A (en) 2024-09-01
JP2025504955A (ja) 2025-02-19
US20250002585A1 (en) 2025-01-02
AU2023210844A1 (en) 2024-08-01
CA3251615A1 (en) 2023-08-03
EP4473012A1 (en) 2024-12-11
WO2023144423A1 (en) 2023-08-03
KR20240137084A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
AR121522A1 (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
MX2018001566A (es) Construcciones de union a antigeno para moleculas diana.
UY37829A (es) Muteínas de interleucina 21 y métodos de tratamiento
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
EA201001734A1 (ru) Улучшенные связывающие молекулы на основе фибронектина и их применение
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
GT201200253A (es) Proteínas terapéuticas de unión a dll4
BR112014025830A8 (pt) Polipeptídeos de ligação ao cd3
CO2019012118A2 (es) Anticuerpo anti-pd-l1 y uso del mismo
ECSP21085693A (es) Moléculas de unión a tigit y pd-1/tigit
PE20121024A1 (es) Moleculas de union biespecificas para la terapia antigiogenesis
MX2022002024A (es) Moleculas de union anti-cd123 multimericas biespecificas y usos de estas.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
CL2022003638A1 (es) Anticuerpos que se unen a cd3
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2022003217A (es) Conjugados terapeuticos.
ECSP099726A (es) Anticuerpos contra la il-25
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
CO2022013406A2 (es) Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2024015391A (es) Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico